Netenax (Netilmicin)

Netilmicin binds to the bacterial 30S ribosomal subunit, causing misreading of messenger RNA and halting protein synthesis. This bactericidal action rapidly kills susceptible Gram‑negative and some Gram‑positive organisms that cause eye infections.

The dosing regimen for Netenax is determined by the prescribing clinician based on the specific infection, severity, patient age and response. Typical regimens involve one to several drops per eye at defined intervals, but the exact schedule should be provided by a qualified healthcare professional.

Safety data for Netilmicin in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant. Healthcare providers should evaluate the individual situation before prescribing.

To place an order, submit an enquiry on the Netenax product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Netenax (Netilmicin) belongs to the aminoglycoside class, offering broad‑spectrum activity against many Gram‑negative ocular pathogens. Compared with fluoroquinolone eye drops, it may have a different resistance profile and is often chosen when fluoroquinolone resistance is a concern. Choice of therapy should be guided by culture results and local resistance patterns.

Netenax should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Do not freeze the product. Keep the container tightly closed when not in use to maintain sterility.

Netenax is applied as sterile eye drops. The patient should wash hands, tilt the head back, pull down the lower eyelid, and instill the prescribed number of drops into the conjunctival sac. The eye should be closed gently for a few seconds to allow absorption, and contact lenses should be removed before administration.

Serious risks, though rare, include corneal epithelial toxicity or ulceration, severe allergic reactions such as Stevens‑Johnson syndrome, and systemic ototoxicity or nephrotoxicity if significant systemic absorption occurs. Patients should report any worsening eye pain, vision changes, rash or swelling promptly.

Netenax should be avoided in individuals with a known hypersensitivity to Netilmicin or other aminoglycosides. Caution is also advised for patients with severe renal impairment, those receiving systemic ototoxic drugs, and pregnant or breastfeeding women unless the benefit outweighs the risk.